Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1665-1670

  Tallman, Martin S ^g   Hakimian, David ^h   Kopecky, Kenneth J ^a   Wheaton, Susan ^h   Wollins, Eric ^h   Foucar, Kathy ^b   Cassileth, Peter A ^c   Habermann, Thomas ^d   Grever, Michael ^e   Rowe, Jacob M ^f   Peterson, LoAnn C ^h  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d MAYO CLINIC   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g NORTHWESTERN UNIVERSITY   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; PENTOSTATIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BONE MARROW; CLADRIBINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PENTOSTATIN; RECURRENCE; REMISSION INDUCTION;

EID: 0032766919     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Piro, L. D., Carrera, C. J., Carson, D. A., and Beutler, E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med., 322: 1117-1121, 1990.
2. Estey, E. H., Kurzrock, R., Kantarjian, H. M., O'Brien, S. M., McCredie, K. B., Beran, M., Koller, C., Keating, M. J., Hirsch-Ginsberg, C., Huh, Y. O., Stass, S., and Freireich, E. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood, 79: 882-887, 1992.
3. Tallman, M. S., Hakimian, D., Variakojis, D., Koslow, D., Sisney, G. A., Rademaker, W., Rose, E., and Kaul, K. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood, 80: 2203-2209, 1992.
4. Hoffman, M. A., Janson, D., Rose, E., and Rai, K. R. Treatment of hairy cell leukemia with cladribine: response, toxicity and long-term follow-up. J. Clin. Oncol., 15: 1138-1142, 1997.
5. Cassileth, P. A., Cheuvart, B., Spiers, A. S. D., Harrington, D. P., Cummings, F. J., Neiman, R. S., Bennett, J. M., and O'Connell, M. J. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol., 9: 243-246, 1991.
6. Kraut, E. H., Bouroncle, B. A., and Grever, M. R. Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol., 7: 168-172, 1989.
7. Johnston, J. B., Eisenhauer, E., Corbett, W. E. N., Scott, J. G., and Zaentz, S. D. Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Natl. Cancer Inst., 80: 765-769, 1988.
8. Annino, L., Ferrari, A., Giona, F., Cimino, G., Crescenzi, S., Cava, C. M., Pacchiarotti, A., and Mandelli, F. Deoxycoformycin induces long-lasting remissions in hairy-cell leukemia: clinical and biological results of two different regimens. Leuk. Lymphoma, 14: 115-119, 1994.
9. Seymour, J. F., Kurzrock, R., Freireich, E. J., and Estey, E. H. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood, 83: 2906-2911, 1994.
10. Tallman, M. S., Hakimian, D., Rademaker, A. W., Zanzig, C., Wollins, E., Rose, E., and Peterson, L. A. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood, 88: 1954-1959, 1996.
11. Saven, A., Burian, C., Koziol, J. A., and Piro, L. D. Long-term follow-up of patients with hairy-cell leukemia after cladribine treatment. Blood, 92: 1918-1926, 1998.
12. Cheson, B. D., Suresen, J. M., Vena, D. A., Montello, M. J., Barrett, J. A., Damasio, E., Tallman, M., Annino, L., Connors, J., Coiffier, B., and Lauria, F. Treatment hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol Mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol., 16: 3007-3015, 1998.
13. Kraut, E. H., Grever, M. R., and Bouroncle, B. A. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood, 84: 4061-4063, 1994.
14. Golomb, H. M., Dodge, R., Mick, R., Budman, D., Hutchison, R., Horning, S. J., and Schiffer, C. A. Pentostatin treatment of hairy cell leukemia patients who fail initial therapy with recombinant α-interferon: a report of CALGB Study 8515. Leukemia, 8: 2037-2040, 1994.
15. Catovsky, D., Matutes, E., Talavera, J. G., O'Connor, N. T. J., Johnson, S. A. N., Emmett, E., Corbett, L., and Swansbury, J. Long-term results with 2′-deoxycoformycin in hairy cell leukemia. Leuk. Lymphoma, 14: 109-113, 1994.
16. Grever, M., Kopecky, K., Foucar, M. K., Head, D., Bennett, J. M., Hutchison, R. E., Corbett, W. E. N., Cassileth, P. A., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., and Cheson, B. D. Randomized comparison of pentostatin versus α-interferon in previously untreated patients with hairy cell leukemia: an intergroup study. J. Clin. Oncol., 13: 974-982, 1995.
17. Flinn, I. W., Kopecky, K. J., Foucar, M. K., Head, D., Bennett, J. M., Hutchinson, R. E., Corbett, W. E. N., Cassileth, P. A., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F. R., Cheson, B. D., and Grever, M. R. Long-term results in hairy cell leukemia (HCL) treated with pentostatin. Blood, 90: 2575a, 1997.
18. Hakimian, D., Tallman, M. S., Kiley, C., and Peterson, L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood, 82: 1798-1802, 1993.
19. Ellison, D. J., Sharpe, R. W., Robbins, B. A., Spinosa, J. C., Leopard, J. D., Saven, A., and Piro, L. D. Immunomorphologic evaluation of post-therapy bone marrows in patients treated with 2-CdA for HCL. Blood, 84: 4310-4315, 1994.
20. Konwalinka, G., Schirmer, M., Hilbe, W., Fend, F., Geisen, F., Knoblechner, A., Petzer, A., and Thaler, J. Minimal residual disease in hairy cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells Mol. Dis., 21: 142-151, 1995.
21. Thaler, J., Denz, H., Dietze, O., Gastl, G., Ho, A. D., Gattringer, C., Greil, R., Lechleitner, M., Huber, C., and Huber, H. Immunohistologic assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with α-2-interferon and deoxycoformycin. Leuk. Res., 13: 377-383, 1989.
22. Thaler, J., Grunewald, K., Gattringer, C., Ho, A. D., Weyrer, K., Dietz, O., Stauder, R., Fluckinger, T., Lang, A., and Huber, H. Long-term follow-up of patients with hairy cell leukemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br. J. Haematol., 84: 75-82, 1993.
23. Matutes, E., Meeus, P., McLennan, K., and Catovsky, D. The significance of minimal residual disease in hairy cell leukemia treated with deoxycoformycin: a long-term follow-up study. Br. J. Haematol., 98: 375-383, 1997.
24. Wheaton, S., Tallman, M. S., Hakimian, D., and Peterson, L. A. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood, 87: 1556-1560, 1996.
25. Cox, D. R. Analysis of Binary Data. London: Chapman and Hall, 1970.
26. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
27. Kalbfleisch, J. D., and Prentice, R. L. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1980.
28. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. Part 1, 50: 163-170, 1996.
29. Cytel Software Corporation. StatXact Turbo User Manual. Cambridge, MA: Cytel Software Corp., 1992.
30. Filleul, B., Delannoy, A., Ferrant, A., Zenebergh, A., Van Daele, S., Bosly, A., Doyen, C., Mineur, P., Glorieux, P., Driesschaert, P., Sokal, G., Martiat, P., and Michaux, J. L. A single course of 2′-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia (Baltimore), 8: 1153-1156, 1994.
31. O'Donnell, L. R., Alder, S. L., Balis, U. J., Perkins, S. L., and Kjeldsberg, C. R. Immunohistochemical reference ranges for B lymphocytes in bone marrow biopsy paraffin sections. Am. J. Clin. Pathol., 104: 517-523, 1995.
32. Betticher, D. C., Fey, M. F., von Rohr, A., Tobler, A., Jenzer, H., Gratwohl, A., Lohri, A., Pugin, P., Hess, U., and Pagani, O. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann. Oncol., 5: 57-64, 1994.
33. Seymour, J. F., Estey, E. H., Keating, M. J., and Kurzrock, R. Response to interferon-α in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia (Baltimore), 9: 929-932, 1995.
34. Juliusson, G., Lenkei, R., Tjonnfjord, G., Heldal, D., and Liliemark, J. Low-dose cladribine for symptomatic hairy cell leukaemia. Br. J. Haematol., 89: 637-639, 1995.